TapImmune to Open New Laboratories and Offices at 1551 Eastlake Ave.
January 18, 2012 09:30 ET
|
TapImmune Inc.
SEATTLE, Jan. 18, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has signed a sub-lease for newly-renovated, state of the art laboratory and office space at 1551 Eastlake Avenue in South Lake...
TapImmune Appoints Mark Reddish to Its Management Team as Vice President Product Development
November 22, 2011 09:30 ET
|
TapImmune Inc.
SEATTLE, Nov. 22, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), is pleased to announce that Mark Reddish has joined its Management Team as Vice President of Product Development. Mark was...
TapImmune Inc. to Collaborate With Nature Immunology and Arkitek Studios
November 02, 2011 09:35 ET
|
TapImmune Inc.
SEATTLE, Nov. 2, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) is pleased to announce a collaboration with Nature Immunology and Arkitek Studios to visualize TAP's role in combating...
TapImmune Inc. and Aeras Start Research & Development Collaboration
October 31, 2011 09:25 ET
|
TapImmune Inc.
SEATTLE, Oct. 31, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) announced that it has signed a Research Collaboration with Aeras. The overall goal of this collaboration will be to evaluate the...
TapImmune Inc. Announces Issuance of US Patent
October 27, 2011 09:35 ET
|
TapImmune Inc.
SEATTLE, Oct. 27, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) announced that the US Patent Office has issued Patent 7,994,146 entitled "Method of Enhancing an Immune Response".
The...
TapImmune to Present at BIT's 2nd Annual World Congress on Immunodiseases and Therapy in Guangzhou, China, November 18, 2011
October 21, 2011 16:00 ET
|
TapImmune Inc.
SEATTLE, Oct. 21, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company developing immunotherapies, today announced that its Chairman and CEO, Dr. Glynn Wilson, is an invited...
TapImmune to Sponsor Phase 1 Breast Cancer Vaccine Trial Following Recent FDA Approval of Investigational New Drug Application
August 11, 2011 16:19 ET
|
TapImmune Inc.
SEATTLE and ROCHESTER, Minn., Aug. 11, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a leading biotechnology company developing immunotherapies, today announced that following FDA IND...
TapImmune Inc to Present at Aegis Capital Emerging Growth Conference in Las Vegas on April 30, 2011
April 28, 2011 09:45 ET
|
TapImmune Inc.
SEATTLE, April 28, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutics and vaccines in the areas of oncology and...
TapImmune Receives Notice of Allowance for U.S. Patent Application Relating to Vaccines Containing TAP for the Treatment of Pox Virus Infections
April 07, 2011 10:42 ET
|
TapImmune Inc.
SEATTLE, April 7, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application...
TapImmune Provides Corporate Update
April 05, 2011 09:20 ET
|
TapImmune Inc.
SEATTLE, April 5, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), is pleased to provide this corporate update to our current and future shareholders and other interested parties.
Our...